ABIOMED, Inc. recently announced that its Impella CP with SmartAssist will be commercially available at the 2019 Society for Cardiovascular Angiography & Interventions (“SCAI”) Scientific Sessions. Additionally, majority of the Impella CP heart pumps will be transitioned to SmartAssist in fiscal 2020.
This fortifies ABIOMED’s foothold in the cardiovascular devices market.
Impella CP With SmartAssist
ABIOMED’s Impella CP with SmartAssist is designed to improve patient outcomes using real-time intelligence. Notably, it received FDA approval in 2018 in the United States.
Impella CP with SmartAssist is the only mechanical circulatory support device that calculates and displays left ventricular end-diastolic pressure, mean arterial pressure and cardiac power output. It is known for greater hemodynamic support.
It is encouraging to note that Impella CP received the Japanese PMDA (Pharmaceuticals and Medical Devices Agency) approval in the recently reported fiscal fourth quarter.
Market Prospects
The Business Research Company suggests that the cardiovascular devices market is expected to reach a value of nearly $80.68 billion by 2022, at a CAGR of 5.7%. New health reforms, a growing economy and rising awareness of healthcare fuel growth.
Price Performance
We believe that positive developments such as these will boost the Zacks Rank #4 (Sell) stock, which has lost 31.3% compared with the industry’s 3.1% decline in a year’s time. The current level compares unfavorably with the S&P 500 index’s 4% rally.
Key Picks
A few better-ranked stocks in the broader medical space are DENTSPLY SIRONA (XRAY - Free Report) , Masimo Corporation (MASI - Free Report) ad CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY’s long-term earnings growth rate is expected at 11.5%.
Masimo’s long-term earnings growth rate is projected at 16.1%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
ABIOMED, Inc. recently announced that its Impella CP with SmartAssist will be commercially available at the 2019 Society for Cardiovascular Angiography & Interventions (“SCAI”) Scientific Sessions. Additionally, majority of the Impella CP heart pumps will be transitioned to SmartAssist in fiscal 2020.
This fortifies ABIOMED’s foothold in the cardiovascular devices market.
Impella CP With SmartAssist
ABIOMED’s Impella CP with SmartAssist is designed to improve patient outcomes using real-time intelligence. Notably, it received FDA approval in 2018 in the United States.
Impella CP with SmartAssist is the only mechanical circulatory support device that calculates and displays left ventricular end-diastolic pressure, mean arterial pressure and cardiac power output. It is known for greater hemodynamic support.
It is encouraging to note that Impella CP received the Japanese PMDA (Pharmaceuticals and Medical Devices Agency) approval in the recently reported fiscal fourth quarter.
Market Prospects
The Business Research Company suggests that the cardiovascular devices market is expected to reach a value of nearly $80.68 billion by 2022, at a CAGR of 5.7%. New health reforms, a growing economy and rising awareness of healthcare fuel growth.
Price Performance
We believe that positive developments such as these will boost the Zacks Rank #4 (Sell) stock, which has lost 31.3% compared with the industry’s 3.1% decline in a year’s time. The current level compares unfavorably with the S&P 500 index’s 4% rally.
Key Picks
A few better-ranked stocks in the broader medical space are DENTSPLY SIRONA (XRAY - Free Report) , Masimo Corporation (MASI - Free Report) ad CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY’s long-term earnings growth rate is expected at 11.5%.
Masimo’s long-term earnings growth rate is projected at 16.1%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CNMD - FREE
Get the latest research report on XRAY - FREE
Get the latest research report on MASI - FREE